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Carcinoma of the large bowel remains the second leading cause of
cancer death in the USA. Over 130 000 new cases are diagnosed
each year, and over 56 000 deaths occur as a result of advanced
disease (Landis et al, 1998). The liver is involved in approximately
60% of patients with advanced disease and is the sole site of initial
tumour recurrence in up to 30% of patients with metastatic disease
(Kemeny and Seiter, 1993). 
Resection of liver metastases has become the mainstay of cura-
tive management of metastatic disease of colorectal origin (Foster
and Berman, 1977), but only a minority of patients are candidates
for surgery. Systemic chemotherapy with 5-fluorouracil (5-FU)
modulated by leucovorin is the most frequently used palliative
treatment. It is associated with a major response rate in approxi-
mately 23% of patients and a median survival of 9–12 months
(Advanced Colorectal Cancer Meta-Analysis Project, 1992).
Recently, a randomized trial showed that the addition of
irinotecan, a camptothecin analog, to 5-FU and leucovorin signifi-
cantly improves response rate and survival in patients with previ-
ously untreated metastatic disease (Douillard et al, 2000). For
patients in whom progressive disease develops following initial 5-
FU-based treatment, the next best available option is irinotecan,
which is associated with a response rate of about 15% and
moderate to severe gastrointestinal and bone marrow toxicity
(Pitot et al, 1997; Rougier et al, 1997). 
In view of the low response rate to 5-FU-based chemotherapy
and the limited effectiveness of second-line treatment, alternatives
to systemic chemotherapy have been evaluated in patients with
liver metastases. The direct infusion of drugs into the hepatic arte-
rial system takes advantage of the fact that hepatic metastases
derive their blood supply fundamentally from the hepatic artery; in
addition, there is evidence of nearly complete first-pass extraction
of the most commonly used drugs. Thus, regional intra-arterial
treatment increases the intratumoural concentration of chemo-
therapy while decreasing the systemic side effects. Moreover, the
increase in intratumoural drug concentration achieved with this
technique makes it possible to overcome the de novo and acquired
cell resistance to chemotherapy (Ensminger and Gyves, 1983).
Response rates ranging from 40–60% have been reported with the
regional intra-arterial approach, mostly in patients without prior
treatment (Kemeny et al, 1987; Chang et al, 1987; Hohn et al,
1989). 
The aim of the present phase II study was to determine the
survival, response rate and toxicity associated with intra-arterial
chemotherapy in patients with colorectal liver metastases refrac-
tory to standard i.v. treatment with 5-FU and leucovorin. Cisplatin
was added to the 5-FU and leucovorin combination on the basis of
the results of in vitro and clinical studies suggesting synergism
between these cytotoxic drugs, although response rate was not
proven to be superior to that of 5-FU and leucovorin alone
(Schabel et al, 1979; Cantrell et al, 1987; Palmeri et al, 1992;
Scheithauer et al, 1991). 
PATIENTS AND METHODS 
The study population consisted of 28 patients with histologically
proven adenocarcinoma of colorectal origin and evidence of non-
resectable liver metastases who showed disease progression during
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systemic chemotherapy with 5-FU 370 mg/m2/d and leucovorin 20
mg/m2/d, days 1–5, every 28 d. Other inclusion criteria were:
  Bi-dimensionally measurable disease documented by
abdominal computerized tomography (CT) 
  Survival expectancy of more than 8 weeks 
  Performance status (PS) 0–2 (ECOG scale) 
  Absolute granulocyte count more than 1000/ul 
  Platelet count more than 100 000/ul 
  Serum bilirubin level less than 1.5 mg/dl 
  Creatinine clearance over 40 ml/min. 
Patients with extrahepatic metastases were entered into the
study provided that the liver disease was considered to be the life-
limiting factor. Two of these patients had local disease and the
third patient had involvement of retroperitoneal lymph nodes. The
protocol was approved by the Institutional Review Committee. All
patients gave informed consent. 
Baseline evaluation consisted of a complete history and physical
examination as well as laboratory studies, including complete blood
count and biochemical profile: liver enzymes, bilirubin, albumin,
coagulation tests (prothrombin time and partial thromboplastin
time), creatinine and creatinine clearance, and serum carcinoembry-
onic antigen (CEA) levels. All patients underwent baseline abdom-
inal and chest CT scan, colonoscopy to rule out local recurrence,
and angiography of the celiac and superior mesenteric arteries to
determine hepatic arterial blood supply to the liver and patency of
the portal vein. Angiography revealed a normal anatomy (type I) in
22 of the 28 patients. In 3 patients, the right hepatic artery arose
from the celiac artery and the left hepatic artery from the left gastric
artery (type II anatomy). In 2 patients, a replaced right hepatic
artery arose from the superior mesenteric artery (type III) and in 1,
the right hepatic artery arose from the superior mesenteric artery,
the left hepatic artery from the left gastric artery, and the middle
hepatic artery from the celiac trunk (type IV). 
Initially patients received treatment via transfemoral catheteri-
zation, with placement of an intra-arterial catheter into the hepatic
artery on day 1 of each cycle. Thereafter, patients who responded
underwent laparotomy for placement of an internal pump (Life
Port Arterial Access System, Strato Medical Corporation, Pfizer,
Beverly, MA, USA) into a s.c. pocket in the upper abdominal wall.
In patients with variant anatomies, treatments were administered
through the different arteries. A technetium-99 macroaggregated
albumin (99mTc-MAA) perfusion study was performed in all
cases to confirm adequate hepatic arterial distribution of the pump
effluent, to exclude extrahepatic perfusion, and to determine the
pulmonary perfusion associated with intratumoural arteriovenous
shunting. In 2 patients a relaparotomy was necessary to relocate a
misplaced catheter. 
The intra-arterial chemotherapy protocol consisted of a combi-
nation of leucovorin 120 mg/m2/d over 30 min followed by 5-FU
700 mg/m2/d diluted in 500 ml of normal saline with 5000 U
heparin infused over 12 h, and cisplatin 20 mg/m2/d diluted in
1000 cc of normal saline with 5000 U heparin infused over 12 h.
This treatment was given daily for 5 consecutive days. Treatment
cycles were repeated every 35–42 d. Patients were pre-medicated
with ondansetron and dexamethasone to decrease emesis. 
Patients were evaluated by weekly blood counts and chemistry
profile. CEA levels were measured before each treatment cycle
and abdominal CT scan was performed every 2 treatments to
evaluate response. 
Complete remission (CR) was defined as the complete disap-
pearance of all evidence of disease on CT scan, partial remission
(PR) as a more than 50% reduction in the sum of the products of
the greatest perpendicular diameters of all tumour lesions on CT
scan and minimal response (MR) as a 25–50% reduction in these
parameters. Stabilization was defined as a reduction of less than
25% in these parameters. 
Drug-related side effects were assessed at each cycle and graded
according to the World Health Organization (WHO) criteria. 
Statistical methods 
Survival, defined as the interval between treatment onset and death
or date of last follow up, was evaluated by univariate and multi-
variate analysis in relation to age, gender, initial stage, PS,
percentage of liver involvement as determined by CT scan, CEA
level and response to treatment. The SPSS software was used to
perform the Kaplan–Meier product limit method (Kaplan and
Meier, 1958). To compare survival between subgroups divided
according to the variables mentioned earlier and between patients
with an objective response to treatment and those with stable or
progressing disease, the log rank test (Peto et al, 1977) was used.
Cox proportional hazards regression models (Cox, 1972) were
applied for multivariate analysis. The relationship between
response rate and all above-mentioned variables was evaluated
with the chi-square test. 
RESULTS 
The characteristics of the 28 patients in the study are shown in
Table 1. The median age was 63 years (range 42–77 years).
Almost half the patients were symptomatic, 9 with PS 1 and 4 with
PS 2 (ECOG scale). In 43% of the patients, more than 50% of the
liver was replaced by tumour. The median CEA level was 109
ng/ml (range 1.2–10 630 ng/ml). Three patients had evidence of
extrahepatic disease, though the liver metastases were considered
the life-limiting factor in each case. Patients received between 1
and 12 cycles of intra-arterial treatment, with a median of 5 cycles
per patient. A total of 150 cycles were delivered. 
Treatment was discontinued because of progression of disease
Table 1 Baseline characteristics of study participants 
No. patients % 
Gender 
Male 16 57 
Female 12 43 
Age (years) 
≤ 65 16 57 
> 65 12 43 
Performance status 
0 15 54 
1 9 32 
2 4 14 
% Liver involvement 
≤ 50 16 57 
> 50 12 43 
CEA (ng/ml) 
≤ 100 14 50 
> 100 14 50 
Extrahepatic disease 
No 25 89 
Yes 3 11 506 A Cyjon et al 
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in the liver in 13 patients (46%) and extrahepatic progression in 7
patients (25%). A total of 5 patients were still receiving
chemotherapy at the time of the analysis. Of the 28 patients, 3
received only one cycle of therapy and were not evaluable for
response due to patient refusal to continue, poor performance
status complicated by deep vein thrombosis, and bowel obstruction
caused by the primary non-resected rectal tumour (1 patient each).
All patients were evaluable for survival and toxicity. 
Response 
Two patients (8%) achieved CR lasting 15 and 19+ months, and 10
patients (40%) achieved PR, for an overall objective response rate
of 48%. None of these patients underwent any surgical procedure
to resect residual tumour. Eleven patients (44%) had stable disease
and in 2 patients (8%), disease progressed despite treatment. The
maximal response was usually documented by the fourth cycle of
treatment. 
In 1 of the 3 patients with extrahepatic disease, a partial
response lasting 12 months was observed. In a second patient, the
disease progressed in the liver while the patient was undergoing
the intra-arterial therapy and the third patient was not evaluable for
response because of bowel obstruction that developed during the
first cycle of intra-arterial therapy. 
Median duration of response in the patients who achieved a
major response was 11.5 months (range 4–19+ months). At the
time of analysis at 6, 8.5, 11, 12 and 19 months, 5 patients were
still in remission. The median time to progression in patients with
stable disease was 6 months (range 2.5–12.5+ months). 
Analysis of the relationship between response and age, gender,
PS, percentage of liver involvement and CEA level showed a
significant correlation only with percentage of liver involvement
(P = 0.029) and CEA level (P = 0.027). Of patients with a tumour
load of 50% or less in the liver, 67% had a major response
compared to only 20% of patients with a greater tumour burden.
Similarly, 69% of patients in whom baseline CEA measured
100 ng/ml or less had a major response compared to 25% of
patients with higher levels. 
Survival 
At a median follow up of 12 months (range 6–29 months), the
median survival for all patients was 12 months (Figure 1). At the
time of data analysis, 7 patients were still alive. 
Univariate analysis showed that percentage of liver involve-
ment, CEA level and response to treatment were all predictive of
survival (Table 2). Patients achieving a major response and
patients with stable or progressive disease had median survivals of
21 and 9 months, respectively (Figure 1). On multivariate analysis,
response to treatment was the most important prognostic factor
(P = 0.000; risk ratio 4.2; 95% CI 1.9–9.5). PS was the only
additional variable with an independent influence on survival
(P = 0.018, risk ratio 1.9; 95% Cl 1.1–3.4). Percentage of liver
involvement and CEA level did not reach statistical significance
with regard to survival (Table 3). 
Toxicity 
Fatigue lasting for several days was an almost universal complaint
associated with treatment. Generally, patients who were fully
active before treatment were able to resume their activities within a
few days after each cycle. In most patients, lactic dehydrogenase,
alkaline phosphatase and alanine aminotransferase levels showed a
marked elevation, up to 3 times the baseline level, during treatment
Table 2 Survival–univariate analysis 
Median
Variable No. patients survival PP-value 
Gender 
Male 16 11.0 
Female 12 13.0 0.738 
Age (years) 
≤ 65 16 9.5 
> 65 12 13.0 0.809 
Performance status 
0 15 13.0 
1–2 13 9.0 0.159 
% Liver involvement 
≤ 50 16 18.0 
> 50 12 8.0 0.003 
CEA (ng/ml) 
≤ 100 14 18.0 
> 100 14 9.0 0.028 
Response* 
CR/PR 12 21.0 
Stable 13 9.0 0.0004 
*Evaluable for response: 25/28 patients.
Table 3 Survival–multivariate analysis 
Variable P-value Risk ratio (95% Cl) 
Gender 0.710 NS 
Age 0.093 NS 
Performance status 0.017 1.9 (1.1–3.4) 
% Liver involvement 0.730 NS 
CEA 0.576 NS 
Response 0.000 4.2 (1.9–9.5) 
NS = not significant. 
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and for 1–2 weeks thereafter, and then reverted to baseline. 
The only significant toxicity, as summarized in Table 4, was
neutropenia grades III and IV, observed in 8 patients (29%). A
total of 5 of these patients, (18%) were hospitalized for 6 episodes
of neutropenic fever, and all recovered with parenteral antibiotics.
Thrombocytopenia grades III and IV occurred in 5 patients (18%),
but was not associated with bleeding episodes. Grades III and IV
gastrointestinal side effects, such as diarrhoea and stomatitis, were
noted in only 3 patients (11%). 
Grade II neurotoxicity requiring discontinuation of cisplatin
was observed in 5 patients (18%); all continued intra-arterial treat-
ment with 5-FU and leucovorin. In 1 patient, treatment was
stopped because of hepatic artery thrombosis. No clinically signif-
icant impairment in renal function was noted. There was no
evident relation between severe side effects and either perfor-
mance status or percentage of liver involvement. However, there
were only 4 patients with PS 2 in our series. There were no treat-
ment-related deaths in the study group. 
DISCUSSION 
Phase III studies of patients with metastatic liver disease of
colorectal origin have consistently yielded higher response rates
for first-line therapy with the direct hepatic approach than with
systemic therapy. In addition, two meta-analyses have revealed a
modest but statistically significant advantage in survival for
patients receiving intra-arterial therapy (Harmantas et al, 1996;
Meta-Analysis Group in Cancer, 1996). Nevertheless, since intra-
arterial chemotherapy requires unique skills and resources and
may be accompanied by specific toxicities, it has not been widely
accepted either as a first-line or second-line treatment after failure
of systemic fluoropyrimidines. Most patients with refractory
disease are treated today with systemic irinotecan (CPT-11). 
In the present study, patients with disease refractory to i.v. 5-FU
and leucovorin were given intra-arterial therapy. A response rate of
48% and a median survival of 12 months were achieved. These
results compare favourably with those of other investigators
treating similar patients with different intra-arterial combinations.
In a subgroup of 29 previously treated patients reported by
Kemeny et al (1994), a response rate of 52% and a median survival
of 13.5 months were attained with intra-arterial fluorodeoxyuri-
dine (FUDR) and leucovorin. Patt et al (1997) reported a response
rate of 33% and a median survival of 15 months in 48 previously
treated patients receiving intra-arterial 5-FU, leucovorin and inter-
feron. The small difference in results between these studies and
ours is most probably attributable to the small number of patients
in each study and the different distribution of known predictive
factors, such as the extent of liver involvement. In our patients, the
median liver involvement was 50%, whereas in the series of
Kemeny et al (1994) and Patt et al (1997), it was 40% and less than
25%, respectively. The liver was the first site of failure in 46% of
our patients, followed by extrahepatic failure in 25%. Similar rates
were reported by the other authors: 64% and 29% (Kemeny et al,
1994) and 48% and 33% (Patt et al, 1997), respectively. The
response rates of 33–52% and median survival of 12–15 months
achieved with intra-arterial chemotherapy in patients with disease
refractory to systemic fluoropyrimidines also compare favourably
with the reported response rates of 13% and 18% and median
survival of 8–11 months for systemic second-line irinotecan (Pitot
et al, 1997; Rougier et al, 1997). Since our study was not a
comparative one, we cannot exclude the possibility that similar
results could be achieved with 5-FU and leucovorin alone. 
In our series, treatment was relatively well tolerated. The most
common complaint was fatigue, which resolved within a few days.
Biliary toxicity, known to be the limiting factor associated with
intra-arterial fluorodeoxyuridine administration (Kemeny and
Ron, 1999), was not observed in any of our patients. 
Despite the lack of randomized studies comparing intra-arterial
with systemic chemotherapy for patients with fluoropyrimidine-
refractory disease, the consistently higher response rates associated
with the regional approach suggest that this modality should be
considered in selected patients with predominant liver disease.
Considering the failure rates of 25–33% in extrahepatic sites in
patients receiving intra-arterial treatment, combining regional
therapy with systemic therapy seems to be a rational approach.
However, this strategy cannot be expected to play a significant role
in improving results due to the low response rates associated with
systemic administration of the currently available drugs. At the
same time, though regional intrahepatic treatment is consistently
associated with a relatively high rate of response, a significant
proportion of patients still fail to respond. Therefore, further clin-
ical trials should explore the effect of intra-arterial combinations
of non-cross-resistant drugs, with possible synergistic effects. In
addition, escalation of doses or a dose-dense approach may also
contribute to decrease the rate of progression of the liver disease.
Since hepatic metastases are the most common cause of death in
patients with colorectal cancer, this approach may ultimately
improve the prognosis of these patients. 
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